The Justice Department's decision to investigate the Federal Reserve comes after a long string of threats by President Donald Trump to go after the central bank's chair, Jerome Powell. Trump told NBC ...

One Chicago's long absence from the small screen is nearly over, with Chicago Fire's winter premiere hitting the airwaves on NBC in the 2026 TV schedule. The long-running drama left off in the fall on ...

Spoiler alert: The following article contains details about the Season 1 finale of Pluribus. Similar to her character in Vince Gilligan’s sci-fi series Pluribus, star Rhea Seehorn ventured into the ...

Reverse: 1999 is a gacha game. Players will pull from active Banners that offer a selection of featured characters ranging in rarity. The rarity of these characters is typically tethered to their ...

Google has removed dozens of AI-generated videos that depicted Disney-owned characters after receiving a cease and desist letter from the studio on Wednesday. Disney flagged the YouTube links to the ...

The animated musical series Hazbin Hotel is no stranger to dark themes, even darker humor, and intricate character backstories. While much of the fandom’s attention is usually on Charlie Morningstar ...

Kendall Myers is a Senior Author with Collider. As part of the TV and Movies Features team, she writes about some of the most popular releases before, during, and after they premiere. In three years, ...

Character.AI received a cease-and-desist letter from Disney, urging the chatbot company to remove Disney characters from among the millions of AI companions on its platform, Variety reports. The ...

Disney‘s lawyers sent a cease-and-desist letter to Character.AI demanding the AI chatbot company remove numerous characters owned by the Mouse House — and accusing the startup of “blatantly infringing ...

Walt Disney sent a cease-and-desist letter to Character.AI, a “personalized superintelligence platform” that the media giant says is ripping off copyrighted characters without authorization. The AI ...

Good morning, everyone. Thank you for joining our next session. Brian Skorney. I'm one of Baird's senior biotech analysts. Very happy to have with us presenting Nurix, it's a company that I cover. And ...